HAWPF (Haw Par) Moat Score: 3/10 (As of Jul. 01, 2026)


HAWPF Haw Par Corp Ltd HAWPF
93 GF Score
Price $12.00
GF Value $8.94
! 3 Warning Signs
View Full Analysis

What is Haw Par Moat Score?

Haw Par HAWPF 93 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates HAWPF with a GF Score™ of 93/100 and a GF Value™ of $8.94. The stock has 3 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Haw Par ranks better than 86.12% on this metric.

Haw Par has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Haw Par has No Moat: Haw Par Corp has a diverse business portfolio, but lacks strong brand strength or significant market leadership in any segment. Its competitive advantages are weak and transient, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Haw Par might have No Moat - Very weak/transient advantages.

Haw Par  (OTCPK:HAWPF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Haw Par Moat Score Related Terms

HAWPF vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Haw Par's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haw Par Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haw Par's Moat Score distribution charts can be found below:

* The bar in red indicates where Haw Par's Moat Score falls into.


HAWPF
93GF Score
Haw Par Corp Ltd HAWPF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Haw Par (HAWPF) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Haw Par ranks #143 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Haw Par's Moat Score too high?
Haw Par's current Moat Score is 3. Based on the distribution chart, Haw Par ranks #143 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #143 out of 1030 companies for Moat Score. This places Haw Par in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Haw Par's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current Moat Score of 3. The stock's GF Value™ is $8.94, compared to a current price of $12.00 — trading 34.2% above its estimated fair value. The current Moat Score is 3. Haw Par's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Haw Par (HAWPF), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haw Par (HAWPF) Overvalued in 2026?

Based on GuruFocus' analysis, Haw Par stock appears to be overvalued. The current stock price of $12.00 is trading 34.2% above its estimated GF Value™ of $8.94.

Key valuation signals for HAWPF:

  • Moat Score: 3
  • GF Value™: $8.94 vs. price of $12.00 (34.2% above fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haw Par Business Description

Other Exchanges H02:SingaporeH4V:Germany
Address 401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
93GF Score

Get the complete analysis for HAWPF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.00
Price
$8.94
GF Value